Healthcare / BiotechnologyNasdaqGM
$28.89
-2.28 (-7.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-59.2M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$545M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.5%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-74.2M · FCF $-60.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Net Income | $-74.2M | $-74.2M | $-58.0M | $-42.8M | $-32.2M | $-119.1M | $-119.7M | $-73.0M | $-46.4M | $-18.6M |
| EBITDA | $-71.5M | $-71.5M | $-56.2M | $-41.2M | $-31.0M | $-117.4M | $-119.0M | $-75.0M | $-45.9M | $-18.3M |
| EPS | — | — | -6.83 | -2.91 | -2.18 | -33.36 | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | -0.05 | -0.13 | 0.09 | — | — | — | — |
| Current Ratio | 18.51 | 18.51 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-60.3M | $-60.3M | $-59.2M | $-41.0M | $-29.7M | $-100.5M | $-100.0M | $-69.3M | $-39.5M | $-16.8M |
| Returns | ||||||||||
| ROE | -29.5% | -29.5% | -41.2% | 50.6% | 70.5% | -70.3% | -47.1% | -39.2% | -37.9% | 80.6% |
| Valuation | ||||||||||
| P/B | 2.15 | 2.15 | 2.93 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||
| EPS Growth | — | — | -135.0% | -33.1% | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.83 → n/d
Residual
+34.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.